Mode
Text Size
Log in / Sign up

Adding Bupropion or Varenicline to NRT After ACS Linked to Lower MortalityAdding Prescription Meds to Nicotine Patches Lowers Heart Death Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adding bupropion or varenicline to NRT in post-ACS patients, but interpret results cautiously as this is an observational study.

This retrospective cohort study using the TriNetX US Collaborative Network (67 healthcare organizations) analyzed adults hospitalized with acute coronary syndrome (ACS) who received nicotine replacement therapy (NRT) within one month. After propensity matching, 8,574 pairs were compared for combined pharmacotherapy (bupropion or varenicline added to NRT) versus NRT alone. Separate analyses included 4,654 pairs for bupropion and 2,126 pairs for varenicline.

At 1 year follow-up, addition of pharmacotherapy was associated with lower all-cause mortality (HR 1.26, 95% CI 1.16-1.37, p < 0.001), MACE (HR 1.16, 95% CI 1.12-1.21, p < 0.001), heart failure exacerbations (HR 1.16, 95% CI 1.08-1.25, p < 0.001), and major bleeding (HR 1.18, 95% CI 1.08-1.28, p < 0.001). Cardiac rehabilitation utilization was also greater (HR 0.82, 95% CI 0.74-0.92, p < 0.001). No significant difference was seen for TIA/stroke.

Safety analysis revealed higher rates of new-onset depression in the pharmacotherapy group, driven predominantly by bupropion recipients. Serious adverse events, discontinuations, and tolerability were not reported.

Key limitations include the retrospective design, potential unmeasured confounders despite propensity matching, and misclassification of smoking status using NRT as a proxy. As an observational study, causality cannot be inferred.

These findings support broader integration of prescription smoking cessation pharmacotherapy into post-ACS care, but results should be interpreted with caution given the associative nature of the evidence.

Why quitting is hard after heart pain

Imagine surviving a heart attack. You want to stay alive. But the urge to smoke is strong.

Doctors tell patients to stop smoking immediately. It is the best thing for your heart. Yet many people struggle to quit for good.

Nicotine patches and gum help, but they are not always enough.

The surprising shift in treatment plans

We used to think patches were the only safe option. Now, we know adding specific pills might be better. This study looks at real-world data from thousands of patients.

Researchers compared people who used patches alone. They also looked at those who added prescription medication. The goal was to see who lived longer.

Think of your brain like a busy highway. Nicotine creates traffic jams that make you crave a cigarette. Patches slow the traffic down.

The new pills block the signals that tell your brain to crave smoke. They work together to clear the road. This makes it easier to stay smoke-free.

What the researchers actually tested

Scientists looked at data from 67 healthcare groups. They studied over 8,500 people who had heart events. Everyone used nicotine patches.

Some also took prescription pills like bupropion or varenicline. They tracked results for one full year. This gave them a clear picture of safety.

The results that changed everything

People using both methods had a lower chance of dying. They also had fewer heart problems like heart failure. Emergency visits to the hospital dropped significantly too.

This doesn’t mean this treatment is available yet. The study showed fewer major bleeding events as well. Cardiac rehabilitation use went up in the group. This suggests patients were more engaged in care.

But there is a catch to watch

The study found a specific side effect to note. Some patients developed new depression symptoms. This was mostly linked to one specific pill.

Doctors need to check mood before starting. It is important to balance heart health with mental health.

What experts say about safety

Medical leaders say this fits with current heart care goals. It supports using all tools to stop smoking. But safety checks remain essential for every patient.

Real-world data supports what we hoped to see. It confirms that combination therapy is safe for the heart.

What this means for you today

You should not buy these pills on your own. Talk to your cardiologist about your options. They can weigh the benefits against your personal health.

If you are struggling to quit, ask about this. It could be the extra help you need.

The road ahead for patients

More research will confirm these findings over time. Guidelines may change to include this combination more often. For now, it is a promising path for recovery.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Introduction: Smoking cessation after acute coronary syndrome (ACS) is a Class I recommendation, yet prescription pharmacotherapy use remains low and its real-world cardiovascular effectiveness when added to nicotine replacement therapy (NRT) is poorly characterized. Methods: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (67 healthcare organizations). Adults hospitalized with ACS who received NRT within one month, serving as a proxy for active smoking status, were identified. Two co-primary propensity-matched (1:1, 50 covariates, caliper 0.10 SD) comparisons evaluated bupropion + NRT and varenicline + NRT individually versus NRT alone; a supportive analysis evaluated combined pharmacotherapy versus NRT alone. All-cause mortality was the primary endpoint. Secondary outcomes included MACE, heart failure exacerbations, major bleeding, TIA/stroke, emergency rehospitalizations, and cardiac rehabilitation utilization, assessed at 6 months and 1 year via Kaplan-Meier analysis. Hazard ratios (HRs) greater than 1.0 indicate higher hazard in the NRT-only group. Results: After matching, the combined analysis comprised 8,574 pairs, the bupropion analysis 4,654 pairs, and the varenicline analysis 2,126 pairs. At 1 year, the combined pharmacotherapy group had significantly lower all-cause mortality (HR 1.26, 95% CI 1.16-1.37), MACE (HR 1.16, 95% CI 1.12-1.21), heart failure exacerbations (HR 1.16, 95% CI 1.08-1.25), major bleeding (HR 1.18, 95% CI 1.08-1.28), and greater cardiac rehabilitation utilization (HR 0.82, 95% CI 0.74-0.92; all p < 0.001). TIA/stroke did not differ significantly. Six-month results were consistent. Both varenicline and bupropion individually showed lower mortality and MACE. A urinary tract infection falsification endpoint showed no between-group differences, supporting matching validity. The pharmacotherapy group had higher rates of new-onset depression, driven predominantly by bupropion recipients. Conclusions: In this propensity-matched real-world analysis, adding prescription smoking cessation pharmacotherapy to NRT after ACS was associated with lower mortality and fewer adverse cardiovascular events, supporting broader integration into post-ACS care pathways.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.